How Tigecycline's Patent Extension Delays Cheaper Generics
Tigecycline, sold as Tygacil by Pfizer, treats complicated skin infections and intra-abdominal infections. Its original patents have expired in many markets, but Pfizer secured extensions through pediatric exclusivity and method-of-use patents, pushing full generic entry to around 2025-2027 in the US.[1] This keeps market exclusivity intact, blocking FDA-approved generics and maintaining high branded pricing.
Current Costs and What Patients Pay
Tygacil costs $1,000-$2,000 per day for a typical course (100mg loading dose, then 50mg twice daily), or $10,000-$20,000 for 10 days, varying by hospital and region.[2] Without generics, US payers like Medicare and insurers cover it at these rates, with patients facing copays of $100-$500 or more. In Europe, similar pricing persists post-2015 patent expiry due to data exclusivity until 2023-2025.[1]
When Generics Could Cut Costs—and Why They Haven't Yet
Pediatric exclusivity added 6 months to US exclusivity (expiring ~2020 for core patents), while secondary patents on formulations and uses extend to 2029 in some cases.[1][3] Generics can't launch until all Orange Book-listed patents and exclusivities clear, via ANDA Paragraph IV challenges—which Pfizer has defended successfully. Expect 50-80% price drops once generics enter, as seen with other antibiotics like levofloxacin.
Challenges to Patents and Their Impact on Pricing
Mylan and Aurobindo filed ANDAs challenging tigecycline patents, leading to ongoing litigation settled or dismissed in Pfizer's favor.[3] If challengers win, generics could arrive sooner, slashing costs immediately. No generics are approved yet; first tentative approvals appeared in 2023, but launches await final patent resolutions.[1]
How This Compares to Similar Antibiotics
Unlike meropenem (generics since 2010, now $50-$200/course) or vancomycin (generics dominant, $100-$500/course), tigecycline's extensions preserve premium pricing amid rising resistant infections.[2] Biosimilar-like generics for small-molecule antibiotics face fewer hurdles than biologics, but tigecycline's narrow indications limit volume, slowing generic investment.
[1]: DrugPatentWatch.com - Tygacil (tigecycline) patents
[2]: GoodRx - Tygacil pricing data
[3]: FDA Orange Book - Tigecycline entries